a kinase of the IKK family. Phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. Preferentially found as a heterodimer with IKK-alpha but also as an homodimer. Note: This description may include information from UniProtKB.
Protein type: Protein kinase, Ser/Thr (non-receptor); EC 188.8.131.52; Protein kinase, Other; Kinase, protein; Other group; IKK family
Chromosomal Location of Human Ortholog: 8p11.2
Cellular Component: internal side of plasma membrane; cytoplasm; IkappaB kinase complex; nucleus; cytosol; lipid raft
Molecular Function: protein serine/threonine kinase activity; protein binding; protein homodimerization activity; IkappaB kinase activity; protein heterodimerization activity; protein kinase binding; ATP binding; protein kinase activity
Biological Process: I-kappaB kinase/NF-kappaB cascade; positive regulation of I-kappaB kinase/NF-kappaB cascade; nerve growth factor receptor signaling pathway; positive regulation of transcription, DNA-dependent; MyD88-independent toll-like receptor signaling pathway; response to virus; toll-like receptor 3 signaling pathway; protein amino acid phosphorylation; T cell receptor signaling pathway; activation of NF-kappaB transcription factor; toll-like receptor 2 signaling pathway; toll-like receptor 10 signaling pathway; MyD88-dependent toll-like receptor signaling pathway; toll-like receptor 5 signaling pathway; serine phosphorylation of STAT protein; B cell homeostasis; toll-like receptor signaling pathway; positive regulation of interferon type I production; innate immune response; positive regulation of transcription from RNA polymerase II promoter; toll-like receptor 9 signaling pathway; I-kappaB phosphorylation; inflammatory response; toll-like receptor 4 signaling pathway; negative regulation of apoptosis
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.